June 2004 Conclusion Slides. June 2004 Bone quality is an integral component of bone strength Maintaining or restoring bone architecture is required for.

Slides:



Advertisements
Similar presentations
Preventing Bone Loss in Early Postmenopausal Women A CME Slide Library From the Council on Hormone Education.
Advertisements

Bone Quality PART 2 Damage Accumulation Degree of Mineralization Biomechanics.
OSTEOPOROSIS An overview of the condition and its treatment
Aging of the Skeletal System Mindy Millard-Stafford, Ph.D. February 5, 1998 Chapter 9- DiGiovanna Underlying question- Aging vs. disuse, abuse?
Lecture 49 Bone Physiology Resorption and Formation Pat O’Connor
Bone Quality PART 1 Introduction Architecture Turnover.
WHO Osteoporosis Definition (1996)
Bone Quality PART 3 Collagen/Mineral Matrix Conclusions Supplemental Slides.
Slide 1 FOSAMAX ™ Once Weekly ACTONEL ™ Once A Week Comparison Trial FOSAMAX™ (alendronate) is a trademark of Merck & Co., Inc, Whitehouse Station, NJ,
Downloaded from 1 Alendronate vs. Risedronate Comparison Trial.
Slide 1 Update on Alendronate and Raloxifene in Osteoporosis EFficacy of FOSALAN ™ vs. Evista ® Comparison Trial (EFFECT) FOSALAN (alendronate) is a trademark.
Assessment of Skeleton Health
Vietnam Osteoporosis Workshop, HCMC 2006 Assessment of Skeleton Health Tuan Van Nguyen and Nguyen Dinh Nguyen Garvan Institute of Medical Research Sydney,
Protelos Long-Term Antifracture Efficacy. Protelos Vertebral Antifracture Efficacy over 4 years in SOTI Favors Protelos  RR P
Copyright © 2012 American College of Sports Medicine Chapter 3 The Skeletal-Articular System Ronald F. Zernicke, Gregory R. Wohl, and Jeremy M. LaMothe.
U.S. Guidance for the Development of Drugs for Osteoporosis: Rationale, Durability and Evolution Henry Bone, M.D. Michigan Bone & Mineral Clinic Detroit,
Bones, Calcium, and Osteoporosis. Bone Bone is living, constantly remodeled Reservoir of Calcium – Calcium levels of blood take precedence over bone levels.
Relationship of Drug Associated Change in Bone Mineral Density to Fracture Risk Marc C. Hochberg, MD, MPH FDA Endocrinologic and Metabolic Drugs Advisory.
Bone Mineral Density Testing March 29, Introduction Osteoporosis is a systemic skeletal disorder characterized by decreased bone mass and deterioration.
Chapter 9 Skeletal health. Chapter overview Introduction Biology of bone Osteoporosis: definition, prevalence and consequences Physical activity and bone.
OSTEOPOROSIS Prof. Dr. Ülkü Akarırmak. Metabolic Bone Diseases Osteosclerosis Osteolysis Osteoporosis is the most common metabolic bone disease.
ECTS symposium 5 Anabolic treatment of osteoporosis.
1 Ipriflavone in the Treatment of Postmenopausal Osteoporosis Randomized placebo-controlled, 4-year study conducted Europe 475 postmenopausal white women,
1 Tuesday 28 Oct 2008 Hall I Session I: 8:00- 10:00 Symposium... 1 Tuesday 28 Oct 2008 Hall I Session I: 8:00- 10:00 Symposium...
Bone Turnover Suppression Based on an ASBMR/ECTS Clincal Debate “Too Much Suppression of Turnover Is Bad for Bone” Co-Chairs: Socrates Papapoulos, Douglas.
TERIPARATIDE (r-hPTH 1-34) Endocrinologic and Metabolic Drugs Advisory Committee Holiday Inn, Bethesda MD July 27, 2001 Bruce S. Schneider, MD CDER FDA.
By Siraya Kitiyodom ปัญหาที่เกี่ยวกับสุขภาพ ที่พบบ่อยในสตรีวัยทอง และวิธีการดูแล (Part II)
June 2004 Bone Quality June 2004 A systemic skeletal disease characterized by low bone mass and microarchitectural deterioration of bone tissue,
Chapter 83 Chapter 83 Denosumab for the Treatment of Osteoporosis Copyright © 2013 Elsevier Inc. All rights reserved.
Susan Broy MD FACP FACR CCD Professor of Clinical Medicine Rosalind Franklin School of Medicine, Chicago Medical School.
Bone mineral density accounts for 70% of bone strength
Download from Slide 1 Update on Alendronate and Raloxifene in Osteoporosis EFficacy of Fosamax ™ vs. Evista ® Comparison.
June 2004 Bone Quality Sourced from NIH Consensus Development Panel on Osteoporosis. JAMA 285: ; 2001 Architecture Turnover Rate Damage Accumulation.
Extended Treatment Effects with Zoledronic Acid Based on Poster 1070 “The Effect of 3 Versus 6 Years of Zoledronic Acid Treatment in Osteoporosis: a Randomized.
Estrogen plus Progestin, BMD and Fractures: Women’s Health Initiative Jane A. Cauley University of Pittsburgh JAMA 2003; 290 (13) :
CONTRIBUTION OF PRECLINICAL STUDIES TO EVALUATION OF OSTEOPOROSIS THERAPY Gideon A Rodan MD PhD Merck Research Laboratories Bone Biology and Osteoporosis.
Chapter 18 Chapter 18 On the Evolution and Contemporary Roles of Bone Remodeling Copyright © 2013 Elsevier Inc. All rights reserved.
The Negative BMU Balance Mean wall thickness (µm)
Session VII Bone healing
Skin, the carotid artery and intervertebral discs: making the connection Mark P. Brincat.
FDA’s Osteoporosis Guidance Center for Drug Evaluation and Research Division of Metabolic and Endocrine Drugs Eric Colman, MD September 25, 2002.
Preclinical Models of Drug Efficacy and Skeletal Toxicity René Rizzoli M.D. Division of Bone Diseases [WHO Collaborating Center for Osteoporosis and Bone.
Ten Years’ Experience with Alendronate for the Treatment of Osteoporosis in Postmenopausal Women Adapted from Bone HG, Hosking D, Devogelaer J-P, Tucci.
MUSCULOSKELETAL BLOCK PATHOLOGY LECTURE 2: MUSCULOSKELETAL BLOCK PATHOLOGY LECTURE 2: CONGENITAL AND DEVELOPMENTAL BONE DISEASES Dr. Maha Arafah Dr. Abdulmalik.
Osteoporosis In Thalassemia Dr Tarek Jawad INT 555.
ANA Testing Carrie Marshall 1/18/08. Osteoporosis Epidemiology The Most Commom Metbolic Disease In The World In US Female>50: Osteoporosis=17% Osteopenia=
Chapter 41: Role of Sex Steroids in the Pathogenesis of Osteoporosis Matthew T. Drake and Sundeep Khosla.
OSTEOPOROSIS. Characteristics of osteoporosis include a reduction of bone density and a change in bone structure, both of which increase susceptibility.
Bone forming drug Pol.Maj.Dr. Tanawat amphansap
Fracture Healing by Dr. Nimer Khraim (DVMS, BVMS, MVSc)
Diagnosis and Treatment of Osteoporosis
Chapter ?? 23 Osteoporosis Nichols and Pavlovic C H A P T E R.
Bone Health & Nutrients Chapter 11 – HLTH 120N. What do you know about your bones?  What is peak bone density?  At about what age do you reach it? 
Chapter 11: Nutrients Involved in Bone Health
Figure 1: Quantitative MicroCT
Copyright © 2005 American Medical Association. All rights reserved.
Suppression of Bone Resorption in OI VI
3Biostatistics, Pacific University, Forest Grove, Oregon, USA
Post Menopausal Osteoporosis
Goal-directed Treatment for Osteoporosis
Fig. 1. Trial profile. From: Randomized Teriparatide [Human Parathyroid Hormone (PTH) 1–34] Once-Weekly Efficacy Research (TOWER) Trial for Examining the.
Drugs for Diseases of Bone
dr. Muh. Ardi Munir, M.Kes, Sp.OT, M.H, FICS
Primary Hyperparathyroidism and Bone
The Roles of Bone Mineral Density, Bone Turnover, and Other Properties in Reducing Fracture Risk During Antiresorptive Therapy  Solomon Epstein, MD  Mayo.
Protein for Healthy Bones
Chapter 45 Osteoporosis in AdultsPhoto Album
Cancer Treatment-Induced Bone Loss (CTIBL) in Prostate Cancer: Pathophysiology, Preclinical Findings, and Treatment with Zoledronic Acid  Theresa A. Guise,
Enrollment and Outcomes
Figure 1. Relative risks of vertebral, hip, and nonvertebral fractures (and 95% CIs) in response to the treatments for ... Figure 1. Relative risks of.
Presentation transcript:

June 2004 Conclusion Slides

June 2004 Bone quality is an integral component of bone strength Maintaining or restoring bone architecture is required for optimal bone quality Bone turnover rate affects the degree of mineralization of bone Optimal collagen/mineral matrix properties contribute to bone quality Bone Quality

June 2004 Bone quality is an integral component of bone strength Maintaining or restoring bone architecture is required for optimal bone quality Bone turnover rate affects the degree of mineralization of bone Bone Quality

June 2004 Raloxifene: Summary of Bone Quality Effects Changes in BMD explain only a small proportion of vertebral fracture risk reduction shown with raloxifene Raloxifene reduces bone turnover to the premenopausal range allowing Repair of microdamage Preservation of heterogeneous mineral distribution A modest increase in mineralization

June 2004 Possible Contributing Factors to the Antifracture Efficacy of Antiresorptives Increase bone mineral density Decrease bone turnover Preserve bone microarchitecture Decrease number of remodeling sites Maintain trabecular thickness and connectivity Decrease number of trabecular perforations

June 2004 Biochemical markers and bone turnover significantly reduced to premenopausal range Normal bone turnover allows adequate repair of microdamage No adverse effect on bone histology Bone Quality Raloxifene

June 2004 Weinstein RS, et al. J Bone Miner Res. 14:S279; 1999 Prestwood KM, et al. J Clin Endocrinol Metab. 85: ; 2000 Ott SM, et al. J Bone Miner Res. 17: ; 2002 Bone Quality Raloxifene Histomorphometry No woven bone No marrow fibrosis No mineralization defect No cellular toxicity (light microscopy) Normal histologic appearance

June 2004 Bone Quality Raloxifene No adverse effects on bone histology Changes in BMD explain only a small proportion of vertebral fracture risk reduction Reduces bone turnover to the normal premenopausal range A moderate increase in mineralization and preservation of heterogeneous mineral distribution Long-term efficacy with sustained fracture reduction in the fourth year of treatment Favorable effects on femoral neck geometry

June 2004 Architecture Increase trabecular thickness and connectivity Increase cortical thickness and improves cortical geometry Favorable effects on femoral neck geometry Turnover Increase formation on quiescent (neutral) surface Increase in formation is greater than resorption (positive bone balance) Transient increase in cortical porosity without impact on bone strength Damage Accumulation Forms new bone Increased bone turnover reduces damage accumulation Bone Quality Conclusions Teriparatide

June 2004 Architecture Increase trabecular thickness and connectivity Increase cortical thickness and improves cortical geometry Favorable effects on femoral neck geometry Turnover Increase formation on quiescent (neutral) surface Increase in formation is greater than resorption (positive bone balance) Transient increase in cortical porosity without impact on bone strength Bone Quality Conclusions Teriparatide

June 2004 Turnover Reduction Within normal physiologic range Preservestrength Decrease resorption cavities Decrease stress risers Decrease perforations Maintain Horizontal struts Maintain Plate-like structure

June 2004 Excessive Turnover Reduction Below normal physiologic range Increasedfragility Insufficient fatigue damage repair Microcrack accumulation Microcrack propagation Prolonged secondary mineralization Excessive mineralization + homogeneous bone ?

June 2004 Osteoporosis Severe Osteoporosis Normal Courtesy Dr. A. Boyde

June 2004 Physiological Range Sourced from Weinstein RS, J Bone Miner Res , 2000 What Is the Optimal Reduction in Bone Turnover for an Antiresorptive Drug? Bone Strength Bone Turnover Excessive turnover Increase in stress risers (weak zones) Increase in perforations Loss of connectivity Insufficient turnover Accumulation of microdamage Increased brittleness due to excessive mineralization

Summary of Bone Quality Effects of Raloxifene and Teriparatide RaloxifeneTeriparatide Cortical geometryProtectImprove Trabecular microarchitectureProtectImprove TurnoverDecreaseIncrease Bone balanceNormalPositive MineralizationNormalFresh bone Mineral heterogeneityNormalIncrease Microdamage Collagen cross-links Osteocyte apoptosis Decrease ? Decrease Decrease? Younger Decrease June 2004

The Assessment of Bone Quality - Advances in Technology

June 2004 Cadaver Vertebrae: FEM vs. BCT Experiments QCT Compressive strength (kN) QCT-BMD x A min (mg/mm) r 2 =0.65, SE=1.11 kN Crawford et al, Bone 2003 Strength (kN) BCT ORS QCT-BMD xA (mg/mm) min Model Strength (kN) June 2004

Virtual Bone Biopsy Wrist detection coils Microscopy-specific MRI scanner software enhancements 3D image processing and analysis

June 2004 Supplemental Slides

June 2004 The Effect of Antiresorptive Therapy on Fracture Healing Study Protocol Cao Y et al. J Bone Miner Res 17: ; 2002 Female OVX rats (n=140) Five study groups Sham control OVX placebo control OVX + estrogen OVX + raloxifene OVX + alendronate Objective: To evaluate the effect of antiresorptives on fracture healing.

June 2004 The Effect of Antiresorptive Therapy on Fracture Healing External Callus Formation Reproduced with permission from Cao Y et al. J Bone Miner Res 17: , Weeks Callus formation Fracture visible 16 Weeks OVX Fracture line dissapeared ALN fracture line still visible Callus width largest in ALN group Fracture repair was delayed with ALN treatment

The Effect of Antiresorptive Therapy on Fracture Healing Photomicrographs of the Callus Reproduced with permission from Cao Y et al. J Bone Miner Res 17: , 2002 ShamOVXEE2RLXALN June 2004

Urinary Markers of Bone Resorption MarkerAbbreviation HydroxyprolineHYP PyridinolinePYD DeoxypyridinolineDPD N-terminal cross-linking telopeptide of type I collagenNTX C-terminal cross-linking telopeptide of type I collagenCTX Delmas PD. J Bone Miner Res 16:2370; 2001

June 2004 Serum Markers of Bone Turnover Abbreviation Formation Bone alkaline phosphatase ALP (BSAP) OsteocalcinOC Procollagen type I C-propeptidePICP Procollagen type I N-propeptidePINP Resorption N-terminal cross-linking telopeptide of type I collagen NTX C-terminal cross-linking telopeptide of type I collagenCTX Tartrate-resistant acid phosphataseTRAP Delmas PD. J Bone Miner Res 16:2370, 2001

Effect of Size on Areal BMD BMC 111 AreaBMD “True” Value = 1 g/cm 3 Adapted from Carter DR, et al. J Bone Miner Res 1992

June 2004 Local Buckling